Bfsg LLC Has $5.60 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Bfsg LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.6% during the 4th quarter, HoldingsChannel reports. The fund owned 24,693 shares of the medical instruments supplier’s stock after selling 1,455 shares during the period. Bfsg LLC’s holdings in Becton, Dickinson and Company were worth $5,602,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BDX. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $26,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company during the third quarter valued at approximately $33,000. Tompkins Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $46,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Barclays increased their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Stock Down 0.1 %

Shares of BDX opened at $224.89 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average price of $232.60 and a two-hundred day moving average price of $233.62. The stock has a market cap of $65.22 billion, a price-to-earnings ratio of 37.36, a P/E/G ratio of 1.65 and a beta of 0.40. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. This represents a 4.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,544 shares of company stock worth $2,370,309 in the last three months. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.